查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371938

到 2030 年靜脈液市場預測：按類型、成分、解決方案類型、袋類型、用途、最終用戶和地區進行的全球分析

Intravenous Solutions Market Forecasts to 2030 - Global Analysis By Type, Composition, Solution Type, Bag Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球靜脈注射解決方案市場規模為 130.9 億美元，預計在預測期內年複合成長率為 10.0%，到 2030 年將達到 255 億美元。

靜脈輸液，也稱為靜脈輸液，是透過靜脈導管注射到患者靜脈中的無菌液體治療劑。靜脈輸液用於恢復和維持患者的液體和電解質平衡，特別是當口服攝取不足或需要快速吸收時。透過將必要的液體和藥物直接輸送到血液中，它可以確保在從醫院到門診病人的各種臨床環境中提供有效的治療和患者支持。

根據2020年美國腸外和經腸營養學會（ASPEN）指南，對於無法接受早期胃腸道營養的高風險患者，應儘早開始經腸營養。

輸液新進展

已經開發出具有改進的穩定性、溶解度和生物利用度的專用製劑。此外，現代組件技術使得靜脈注射解決方案的產生成為可能，能夠提供更多種類的治療劑，包括複雜的藥物和營養素。由於新興市場的開拓，治療效果的提高使得治療更廣泛的醫學疾病成為可能，市場基礎也擴大了。因此，靜脈輸液市場受益於更先進和專業的解決方案的可用性，這些解決方案改善了患者照護和治療結果，顯著促進了市場成長。

高成本

靜脈注射製劑可能很昂貴，特別是如果它們使用複雜的成分或專門的製劑。此外，製造、包裝和品管價格也會影響輸液的總成本。因此，這種定價可能會限制市場准入，特別是在資源有限或醫療保健基礎設施薄弱的地區。

提高認知

隨著人們健康意願的增強，對預防性和整體保健方法的需求不斷增加。靜脈輸液不僅是為了醫療目的，也是為了健康和活力。它經常用於供給、免疫支持和營養供給。此外，客製化靜脈注射療法作為減少缺陷、增加能量和改善整體健康的一種方式越來越受歡迎。此外，診所和提供者正在提供靜脈注射解決方案，以滿足意願健康的一代人的健康和表現目標，這正在推動市場規模。

缺乏標準化和品質

產品性能和品質的一致性對於病患安全至關重要，但可能會受到各種品質和安全標準的阻礙。此外，各地區缺乏統一的法規導致製造實務和產品標籤存在差異，這使得醫療保健專業人員在確保靜脈輸液的可靠性方面面臨挑戰。因此，缺乏標準化和法律規範導致市場風險和複雜性增加，需要全面的、全球認可的標準來確保這些重要醫療產品的安全性和有效性，這強調了指南的必要性。

COVID-19 的影響

靜脈輸液市場受到 COVID-19 爆發的嚴重負面影響。醫療機構面臨罕見的資源緊張，而且常常負擔過重。這導致了尋找和分配這些重要醫療輸液的短缺和後勤困難。此外，經濟危機和不確定性阻礙了醫療保健產業的投資。因此，儘管需求增加，但大流行給靜脈輸液市場帶來了物流和財務挑戰，對可用性和供應產生了負面影響。

預計葡聚醣細分市場在預測期內將是最大的細分市場

據估計，右旋糖酐領域在醫療機構中佔據最大佔有率，因為它主要用於促進血液流動並減少手術和其他醫療程序期間形成血栓的可能性。此外，這些基於葡聚醣的靜脈注射溶液可作為血漿擴張劑，促進血液循環並幫助維持血壓。這些對於患者出血或需要血流動力學支持的情況至關重要。因此，基於葡聚醣的靜脈注射液已成為醫療保健領域更大的靜脈注射液市場的重要組成部分，因為它們對於在醫療活動期間維持患者的健康至關重要。

大容量箱包領域預計在預測期間內年複合成長率最高

預計大容量箱包市場在預測期內的年複合成長率最高。這些袋子在醫療保健領域的多種用途中是不可或缺的，包括營養輸送、給藥和供給。此外，醫院、診所和其他醫療機構經常使用大容量輸液袋，為患者提供有效且受控的靜脈治療。大容量輸液袋是醫療保健產業靜脈注射解決方案市場的支柱，因為它們可以靈活地容納不同類型的輸液，這對於需要長期治療的患者尤其重要。

比最大的地區

由於醫療保健系統中龐大的患者群體、重要參與者的崛起、藥物的容易獲得、醫療保健系統的複雜性以及有利的報銷做法，歐洲在預測期內獲得了最大的市場佔有率。此外，由於政府對國民醫療服務和健康保險的支持以及該行業的技術進步，歐洲靜脈輸液市場可能會發展。而且，英國靜脈輸液市場市場佔有率最高，法國靜脈輸液市場在歐洲大陸擴張最快。

複合年複合成長率最高的地區：

由於快速成長，預計亞太地區在預測期內複合年複合成長率最高。這是由於公共和私營部門對研究的大量投資，以及技術開發、醫療保健行業和大學等各相關人員之間加強的合作。因此，不健康的食品消費模式導致的慢性病患病上升以及對具有成本效益的護理選擇的增加是預計推動亞太地區市場成長的兩個關鍵要素。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球輸液解決方案市場：按類型

  • 完全腸外營養
  • 部分腸外營養

第6章 全球靜脈注射藥物市場：依結構

  • 碳水化合物
  • 維生素和礦物質
  • 腸外脂肪乳劑
  • 單給藥胺基酸
  • 其他結構

第7章 全球輸液解決方案市場：依解決方案類型

  • 葡聚醣
  • 生理食鹽水
  • 高滲透壓鹽水
  • 胺基酸
  • 生理食鹽水
  • 乳酸林格氏液
  • 肝素和微量元素
  • 維生素和礦物質
  • 混合溶液

第8章 全球靜脈藥品市場：按袋類型

  • 大容量袋
  • 小容量袋

第9章 全球輸液解決方案市場：依應用分類

  • 營養滴注液
  • 輸血
  • 基本靜脈注射液
  • 灌輸液
  • 藥物滴注液

第10章 全球輸液解決方案市場：依最終用戶分類

  • 診所
  • 醫院
  • 門診手術中心
  • 家庭護理設置

第11章全球輸液解決方案市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章公司簡介

  • ICU Medical, Inc.
  • B. Braun Melsungen Ag
  • JW Life Science
  • Baxter International Inc.
  • Fresenius Kabi USA, LLC
  • Vifor Pharma Management Ltd
  • Amanta Healthcare
  • Grifols, SA
  • Salius Pharma Private Limited.
  • Pfizer, Inc.
  • Axa Parenterals Ltd
  • Ajinomoto Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Soxa Formulations & Research Pvt. Ltd
  • Braun Melsungen AG
Product Code: SMRC23995

According to Stratistics MRC, the Global Intravenous Solutions Market is accounted for $13.09 billion in 2023 and is expected to reach $25.5 billion by 2030 growing at a CAGR of 10.0 % during the forecast period. Intravenous solutions, also called IV solutions, are sterile liquid treatments that are injected into a patient's veins by means of an intravenous line. These treatments are used for a variety of essential medical functions, such as rehydration, medicine delivery, and nutritional support, IV solutions are used to restore and maintain a patient's fluid and electrolyte balance, particularly when oral intake is insufficient or rapid absorption is required. They are composed of a precisely balanced blend of water, nutrients, and sometimes drugs and are a crucial part of contemporary healthcare, guaranteeing efficient treatment and patient support in a range of clinical settings, from hospitals to outpatient care, by supplying necessary fluids and medicinal chemicals straight into the bloodstream.

According to the guidelines by American Society for Parenteral and Enteral Nutrition (ASPEN), in 2020, the early parenteral nutrition should be initiated as soon as possible in the high-risk patient for whom early gastric enteral nutrition is not feasible.

Market Dynamics:

Driver:

New developments in IV solutions

As the developments involve the creation of specialized formulations with improved stability, solubility, and bioavailability. Additionally, modern ingredient technology makes it possible to create intravenous solutions that can transport a wider variety of therapeutic agents, such as complicated drugs and nutrients. As a result of these developments, it is now possible to treat a wider range of medical diseases by improving treatment efficacy and broadening the market's capacities. Therefore, the market for intravenous solutions benefits from being able to provide more sophisticated and specialized solutions, which enhance patient care and treatment outcomes and thus significantly drives the market growth.

Restraint:

High cost

IV solutions can be pricey, especially when made with complicated ingredients or in specialist formulations. Moreover, the price of manufacturing, packaging, and quality control can affect the overall cost of IV solutions. Hence, this pricing aspect may restrict market access, particularly in areas with limited resources or poor healthcare infrastructure.

Opportunity:

Increase in awareness

Preventive and holistic healthcare methods are in greater demand as people grow more health-conscious. Intravenous solutions are in demand not just for medical treatment but also for wellness and vitality reasons. They are frequently used for rehydration, immunological support, and nutrient supplementation. Furthermore, customized IV therapy is becoming more and more popular as a way to reduce deficiencies, increase energy, and improve general wellbeing. Moreover, clinics and providers offer intravenous solutions that meet the wellness and performance objectives of a health-conscious generation, which thus propel the market size.

Threat:

Lack of standardization and quality

The consistency of product performance and quality, which is essential for patient safety, might be hampered by varying quality and safety standards. Moreover, the absence of unified regulations across regions can lead to disparities in manufacturing practices and product labeling, making it challenging for healthcare providers to ensure the reliability of intravenous solutions. Therefore, this lack of standardization and regulatory oversight can result in increased risks and complexities in the market, emphasizing the need for comprehensive, globally recognized guidelines to ensure the safety and efficacy of these critical medical products.

COVID-19 Impact

The market for intravenous solutions was significantly negatively impacted by the COVID-19 epidemic. Healthcare facilities experienced rare resource pressures and were frequently overburdened, which resulted in shortages and logistical difficulties when locating and dispensing these vital medical fluids. Additionally, investments in the healthcare industry were impeded by the economic collapse and uncertainties. Therefore, despite rising demand, the pandemic posed logistical and financial challenges for the market for intravenous solutions, adversely impacting both accessibility and supply.

The Dextran segment is expected to be the largest during the forecast period

The Dextran segment is estimated to hold the largest share, as these treatments are used in healthcare facilities to boost blood flow and lower the chance of clot formation, primarily during operations and other medical procedures. Additionally, these IV solutions based on dextran, function as plasma expanders, enhancing circulation and assisting in blood pressure maintenance. They are crucial in circumstances where patients can experience bleeding or need hemodynamic support. Thus, intravenous solutions based on dextran are an essential part of the larger intravenous solutions market in the healthcare sector since they are essential in sustaining patient wellbeing during medical operations.

The large volume bags segment is expected to have the highest CAGR during the forecast period

The large volume bags segment is anticipated to have highest CAGR during the forecast period, due to a variety of uses in healthcare, such as nutrient delivery, medicine administration, and hydration, these bags are essential. Moreover, in hospitals, clinics, and other medical facilities, large-volume bags are frequently utilized to deliver effective and controlled intravenous therapy to patients. Hence, they are a backbone of the intravenous solutions market in the healthcare industry because they are flexible in accepting different types of solutions and are especially important for patients needing prolonged treatments.

Region with largest share:

Europe commanded the largest market share during the extrapolated period owing to the healthcare system's enormous patient population, the prominence of important players, the accessibility of drugs, the sophistication of the healthcare systems, and the advantageous reimbursement practices. Furthermore, the market for intravenous (IV) solutions in Europe will probably develop as a result of government support for the National Health Service and health insurance as well as industry technological advancements. Additionally, the intravenous solution market in the United Kingdom had the highest market share, while the intravenous solution market in France had the quickest rate of expansion in the continent of Europe.

Region with highest CAGR:

Asia Pacific is expected to witness highest CAGR over the projection period, owing to rapid growth, which can be attributed to the high investment made in research by both public and private entities, as well as technological developments and an increase in the number of cooperative relationships between different stakeholders, including the healthcare industry, universities, and others. Therefore, the rising prevalence of chronic diseases brought on by unhealthy food consumption patterns and the growing choice for cost-effective care are two significant factors that are projected to propel market growth in the Asia Pacific region.

Key players in the market:

Some of the key players in the Intravenous Solutions Market include: ICU Medical, Inc., B. Braun Melsungen Ag, JW Life Science, Baxter International Inc., Fresenius Kabi USA, LLC, Vifor Pharma Management Ltd, Amanta Healthcare, Grifols, S.A, Salius Pharma Private Limited., Pfizer, Inc., Axa Parenterals Ltd, Ajinomoto Co., Inc., Otsuka Pharmaceutical Co., Ltd, Sichuan Kelun Pharmaceutical Co Ltd, Soxa Formulations & Research Pvt. Ltd and Braun Melsungen AG.

Key Developments:

In March 2022, Otsuka Pharmaceutical received regulatory approval in Japan for the sale of SAMTASU intravenous infusion for treating cardiac edema.

In February 2022, B. Braun Medical received the US FDA approval to begin operations at its new IV saline solution manufacturing facility in Daytona Beach, Florida.

In September 2021, B. Braun Medical Inc. launched CARESAFE IV Administration Sets with an Optional AirStop component.

In July 2021, Grifols S.A. announced the establishment of an intravenous (IV) solutions production plant in Nigeria.

Types Covered:

  • Total Parenteral Nutrition
  • Partial Parenteral Nutrition

Compositions Covered:

  • Carbohydrates
  • Vitamins and Minerals
  • Parenteral Lipid Emulsion
  • Single Dose Amino Acids
  • Other Compositions

Solution Types Covered:

  • Dextran
  • Saline
  • Hypertonic Saline
  • Amino Acid
  • Normal Saline
  • Lactated Ringer's
  • Heparin And Trace Elements
  • Vitamins & Minerals
  • Mixed Solutions

Bag Types Covered:

  • Large Volume Bags
  • Small Volume Bags

Applications Covered:

  • Nutritional IV Solution
  • Blood IV Solution
  • Basic IV Solution
  • Irrigation IV Solution
  • Drug IV Solution

End Users Covered:

  • Clinics
  • Hospital
  • Ambulatory Surgery Centers
  • Home Care Settings

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact Of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Intravenous Solutions Market, By Type

  • 5.1 Introduction
  • 5.2 Total Parenteral Nutrition
  • 5.3 Partial Parenteral Nutrition

6 Global Intravenous Solutions Market, By Composition

  • 6.1 Introduction
  • 6.2 Carbohydrates
  • 6.3 Vitamins And Minerals
  • 6.4 Parenteral Lipid Emulsion
  • 6.5 Single Dose Amino Acids
  • 6.6 Other Compositions

7 Global Intravenous Solutions Market, By Solution Type

  • 7.1 Introduction
  • 7.2 Dextran
  • 7.3 Saline
  • 7.4 Hypertonic Saline
  • 7.5 Amino Acid
  • 7.6 Normal Saline
  • 7.7 Lactated Ringer's
  • 7.8 Heparin And Trace Elements
  • 7.9 Vitamins & Minerals
  • 7.1 Mixed Solutions

8 Global Intravenous Solutions Market, By Bag Type

  • 8.1 Introduction
  • 8.2 Large Volume Bags
  • 8.3 Small Volume Bags

9 Global Intravenous Solutions Market, By Application

  • 9.1 Introduction
  • 9.2 Nutritional IV Solution
  • 9.3 Blood IV Solution
  • 9.4 Basic IV Solution
  • 9.5 Irrigation IV Solution
  • 9.6 Drug IV Solution

10 Global Intravenous Solutions Market, By End User

  • 10.1 Introduction
  • 10.2 Clinics
  • 10.3 Hospital
  • 10.4 Ambulatory Surgery Centers
  • 10.5 Home Care Settings

11 Global Intravenous Solutions Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 ICU Medical, Inc.
  • 13.2 B. Braun Melsungen Ag
  • 13.3 JW Life Science
  • 13.4 Baxter International Inc.
  • 13.5 Fresenius Kabi USA, LLC
  • 13.6 Vifor Pharma Management Ltd
  • 13.7 Amanta Healthcare
  • 13.8 Grifols, S.A
  • 13.9 Salius Pharma Private Limited.
  • 13.10 Pfizer, Inc.
  • 13.11 Axa Parenterals Ltd
  • 13.12 Ajinomoto Co., Inc.
  • 13.13 Otsuka Pharmaceutical Co., Ltd
  • 13.14 Sichuan Kelun Pharmaceutical Co Ltd
  • 13.15 Soxa Formulations & Research Pvt. Ltd
  • 13.16 Braun Melsungen AG

List of Tables

  • Table 1 Global Intravenous Solutions Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Intravenous Solutions Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Intravenous Solutions Market Outlook, By Total Parenteral Nutrition (2021-2030) ($MN)
  • Table 4 Global Intravenous Solutions Market Outlook, By Partial Parenteral Nutrition (2021-2030) ($MN)
  • Table 5 Global Intravenous Solutions Market Outlook, By Composition (2021-2030) ($MN)
  • Table 6 Global Intravenous Solutions Market Outlook, By Carbohydrates (2021-2030) ($MN)
  • Table 7 Global Intravenous Solutions Market Outlook, By Vitamins And Minerals (2021-2030) ($MN)
  • Table 8 Global Intravenous Solutions Market Outlook, By Parenteral Lipid Emulsion (2021-2030) ($MN)
  • Table 9 Global Intravenous Solutions Market Outlook, By Single Dose Amino Acids (2021-2030) ($MN)
  • Table 10 Global Intravenous Solutions Market Outlook, By Other Compositions (2021-2030) ($MN)
  • Table 11 Global Intravenous Solutions Market Outlook, By Solution Type (2021-2030) ($MN)
  • Table 12 Global Intravenous Solutions Market Outlook, By Dextran (2021-2030) ($MN)
  • Table 13 Global Intravenous Solutions Market Outlook, By Saline (2021-2030) ($MN)
  • Table 14 Global Intravenous Solutions Market Outlook, By Hypertonic Saline (2021-2030) ($MN)
  • Table 15 Global Intravenous Solutions Market Outlook, By Amino Acid (2021-2030) ($MN)
  • Table 16 Global Intravenous Solutions Market Outlook, By Normal Saline (2021-2030) ($MN)
  • Table 17 Global Intravenous Solutions Market Outlook, By Lactated Ringer's (2021-2030) ($MN)
  • Table 18 Global Intravenous Solutions Market Outlook, By Heparin And Trace Elements (2021-2030) ($MN)
  • Table 19 Global Intravenous Solutions Market Outlook, By Vitamins & Minerals (2021-2030) ($MN)
  • Table 20 Global Intravenous Solutions Market Outlook, By Mixed Solutions (2021-2030) ($MN)
  • Table 21 Global Intravenous Solutions Market Outlook, By Bag Type (2021-2030) ($MN)
  • Table 22 Global Intravenous Solutions Market Outlook, By Large Volume Bags (2021-2030) ($MN)
  • Table 23 Global Intravenous Solutions Market Outlook, By Small Volume Bags (2021-2030) ($MN)
  • Table 24 Global Intravenous Solutions Market Outlook, By Application (2021-2030) ($MN)
  • Table 25 Global Intravenous Solutions Market Outlook, By Nutritional IV Solution (2021-2030) ($MN)
  • Table 26 Global Intravenous Solutions Market Outlook, By Blood IV Solution (2021-2030) ($MN)
  • Table 27 Global Intravenous Solutions Market Outlook, By Basic IV Solution (2021-2030) ($MN)
  • Table 28 Global Intravenous Solutions Market Outlook, By Irrigation IV Solution (2021-2030) ($MN)
  • Table 29 Global Intravenous Solutions Market Outlook, By Drug IV Solution (2021-2030) ($MN)
  • Table 30 Global Intravenous Solutions Market Outlook, By End User (2021-2030) ($MN)
  • Table 31 Global Intravenous Solutions Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 32 Global Intravenous Solutions Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 33 Global Intravenous Solutions Market Outlook, By Ambulatory Surgery Centers (2021-2030) ($MN)
  • Table 34 Global Intravenous Solutions Market Outlook, By Home Care Settings (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.